美国提议禁止中国医疗科技公司参与联邦合同的法案导致药明康德和药明生物的股价大幅下跌。 US bill proposing to ban Chinese medical tech firms from federal contracts leads to significant stock decline for WuXi AppTec and Wuxi Biologics.
在美国提出一项提议禁止中国医疗技术公司及其子公司获得联邦合同的法案后，药明康德和药明生物的股价大幅下跌。 WuXi AppTec and Wuxi Biologics experienced significant stock declines following the introduction of a US bill proposing to ban the Chinese medical technology companies and their units from accessing federal contracts. 正如民主党参议员加里·彼得斯所说，拟议的立法旨在保护美国个人健康和遗传信息免受外国对手的侵害。 The proposed legislation aims to protect American personal health and genetic information from foreign adversaries, as stated by Democratic Senator Gary Peters. 市场对这项立法的反应尚不清楚。 The market reaction to this legislation was not immediately clear.